tn tonal Application No FC 1/GB2004/005080

| A. CLASSI IPC 7 | FICATION OF SUBJECT MATTER CO7F9/00 A61K31/28 A61P5/00 | A61P25/00 | | |
|--|---|--|---|--|
| According to | nternational Patent Classification (IPC) or to both national classifica | ttlen and IPC | | |
| B. FIELDS | | | | |
| Minimum do | cumentation searched (classification system followed by classification CO7F A61K A61P | on symbols) | | |
| Documental | ion searched other than minimum documentation to the extent that so | uch documents are included in the fields se | arched | |
| Electronic d | ata base consulted during the international search (name of data bas | se and, where practical, search terms used |) | |
| EPO-In | ternal, CHEM ABS Data | | | |
| C. DOCUMI | ENTS CONSIDERED TO BE RELEVANT | | | |
| Category * | Citation of document, with Indication, where appropriate, of the rela | evant passages | Relevant to claim No. | |
| P,X | SCHMID, ANNETTE C. ET AL: "Bisperoxovanadium compounds are PTEN inhibitors" FEBS LETTERS, 566(1-3), 35-38 CO FEBLAL; ISSN: 0014-5793, 2004, XP the whole document | DEN: | 1-12 | |
| Х | glucose transport as powerfully a and contractions combined" DIABETES , 52(8), 1918-1925 CODEN ISSN: 0012-1797, 2003, XP00231847 the whole document | eroxovanadium compound stimulates muscle lucose transport as powerfully as insulin nd contractions combined" IABETES , 52(8), 1918-1925 CODEN: DIAEAZ; SSN: 0012-1797, 2003, XP002318470 | | |
| | | | | |
| | | | | |
| X Furti | her documents are listed in the continuation of box C. | X Patent family members are listed in | л алпех. | |
| *A* docume | ent defining the general state of the art which is not dered to be of particular relevance | "T later document published after the linte or priority date and not in conflict with cited to understand the principle or the invention | the application but sory underlying the | |
| filing of the color of the colo | iate ant which may throw doubts on priority claim(s) or | "X" document of particular relevance; the c cannot be considered novel or cannot involve an inventive step when the do "Y" document of particular relevance; the c cannot be considered to involve an inv document is combined with one or mo | be considered to current is taken alone taimed invention wentive step when the | |
| other i | means ent published prior to the international filing date but | ments, such combination being obvious in the art. *& document member of the same patent | us to a person skilled | |
| | nan the priority date claimed actual completion of the international search | Date of malling of the international sea | | |
| 1 | March 2005 | 10/03/2005 | | |
| Name and r | mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 | Authorized officer | | |
| | NI 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016 | Rinkel, L | | |

Form PCT/ISA/210 (second sheet) (January 2004)

Application No /GB2004/005080

| Citation of document, with indication, where appropriate, of the relevant passages BAND, CHRISTIAN J. ET AL: "Early | Relevant to claim No. |
|--|---|
| | 1-8,12 |
| signaling events triggered by peroxovanadium 'bpV(phen)! are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase (s) by bpV(phen)" MOLECULAR ENDOCRINOLOGY , 11(13), 1899-1910 CODEN: MOENEN; ISSN: 0888-8809, 1997, XP002318471 the whole document | , |
| BAND, CHRISTIAN J. ET AL: "Phosphatidylinositol 3'-kinase and p70s6k are required for insulin but not bisperoxovanadium 1,10-phenanthroline (bpV(phen)) inhibition of insulin-like growth factor binding protein gene expression. Evidence for MEK-independent activation of mitogen-activated protein kinase by bpV(phen)" JOURNAL OF BIOLOGICAL CHEMISTRY, 272(1), 138-145 CODEN: JBCHA3; ISSN: 0021-9258, 1997, XP002318472 cited in the application the whole document | 1-8,12 |
| US 2003/055106 A1 (FAURE, ROBERT ET AL) 20 March 2003 (2003-03-20) the whole document | 1-8,12 |
| BARAT, CORINNE ET AL: "Treatment of Human T Cells with Bisperoxovanadium Phosphotyrosyl Phosphatase Inhibitors Leads to Activation of Cyclooxygenase-2 Gene" JOURNAL OF BIOLOGICAL CHEMISTRY, 278(9), 6992-7000 CODEN: JBCHA3; ISSN: 0021-9258, 2003, XP002318473 the whole document | 1-8,12 |
| WO 00/57860 A2 (CENTRE FOR TRANSLATIONAL RESEARCH IN CANCER, CAN.) 5 October 2000 (2000-10-05) the whole document | 1-8,12 |
| WO 2004/018655 A2 (NEURONOVA AB, SWED.) 4 March 2004 (2004-03-04) the whole document | 1-8,12 |
| | receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase (s) by bpV(phen)" MOLECULAR ENDOCRINOLOGY , 11(13), 1899-1910 CODEN: MOENEN; ISSN: 0888-8809, 1997, XP002318471 the whole document BAND, CHRISTIAN J. ET AL: "Phosphatidylinositol 3'-kinase and p70s6k are required for insulin but not bisperoxovanadium 1,10-phenanthroline (bpV(phen)) inhibition of insulin-like growth factor binding protein gene expression. Evidence for MEK-independent activation of mitogen-activated protein kinase by bpV(phen)" JOURNAL OF BIOLOGICAL CHEMISTRY , 272(1), 138-145 CODEN: JBCHA3; ISSN: 0021-9258, 1997, XP002318472 cited in the application the whole document US 2003/055106 A1 (FAURE, ROBERT ET AL) 20 March 2003 (2003-03-20) the whole document BARAT, CORINNE ET AL: "Treatment of Human T Cells with Bisperoxovanadium Phosphotyrosyl Phosphatase Inhibitors Leads to Activation of Cyclooxygenase-2 Gene" JOURNAL OF BIOLOGICAL CHEMISTRY , 278(9), 6992-7000 CODEN: JBCHA3; ISSN: 0021-9258, 2003, XP002318473 the whole document WO 00/57860 A2 (CENTRE FOR TRANSLATIONAL RESEARCH IN CANCER, CAN.) 5 October 2000 (2000-10-05) the whole document WO 2004/018655 A2 (NEURONOVA AB, SWED.) 4 March 2004 (2004-03-04) the whole document |

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

Application No PC1/GB2004/005080

| | (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT alegory * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. | | | | | | |
|------------|--|--------------------|--|--|--|--|--|
| Category * | Citation of document, with indication, where appropriate, or the reservant bassages | nessen to Gain No. | | | | | |
| Х | SASAGAWA, TAKAHIRO ET AL: "Bis(6-ethylpicolinato)oxovanadium(IV) complex with normoglycemic activity in KK-Ay mice" JOURNAL OF INORGANIC BIOCHEMISTRY, 88(1), 108-112 CODEN: JIBIDJ; ISSN: 0162-0134, 2002, XP002318474 the whole document | 10,12 | | | | | |
| X | KOZLOV, ALEXANDER ET AL: "Zeolite-encapsulated vanadium picolinate peroxo complexes active for catalytic hydrocarbon oxidations" JOURNAL OF MOLECULAR CATALYSIS A: CHEMICAL , 137(1-3), 223-237 CODEN: JMCCF2; ISSN: 1381-1169, 1999, XP002318475 the whole document | 10 | | | | | |
| P,X | GB 2 396 106 A (JOHNSON & JOHNSON MEDICAL LIMITED, UK) 16 June 2004 (2004-06-16) the whole document | 1-8,12 | | | | | |
| | | | | | | | |

Application No PC1/GB2004/005080

| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
|---|------|---------------------|------|----------------------------|----|---------------------|
| US 2003055106 | A1 | A1 20-03-2003 | CA | 2280249 | A1 | 12-02-2001 |
| ••• | | | AU | 6550900 | Α | 13-03-2001 |
| | | | BR | 0013147 | Α | 23-07-2002 |
| | | | WO | 0112180 | A2 | 22-02-2001 |
| | | | CA | 2314915 | A1 | 12-02-2001 |
| | | | EP | 1202728 | A2 | 08-05-2002 |
| | | | JP | 2003506487 | T | 18-02-2003 |
| | | | MX | PA02001481 | Α | 21-07 - 2003 |
| | | | NZ | 517159 | Α | 30-04-2004 |
| WO 0057860 | . A2 | 05-10-2000 | AU | 3412600 | Α | 16-10-2000 |
| | | | CA | 2365122 | A1 | 05-10-2000 |
| | | | EP | 1165098 | A2 | 02-01-2002 |
| WO 2004018655 | A2 | 04-03-2004 | NONE | | | |
| GB 2396106 | A | 16-06-2004 | WO | 2004052412 | A1 | 24-06-2004 |

Form PCT/ISA/210 (patent family annex) (January 2004)